XML 26 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Series B Convertible Preferred Stock [Member]
Convertible Preferred Stock [Member]
Convertible Preferred Stock [Member]
Series B Convertible Preferred Stock [Member]
Common Stock [Member]
Common Stock [Member]
Series B Convertible Preferred Stock [Member]
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
Series B Convertible Preferred Stock [Member]
Accumulated Other Comprehensive Income [Member]
Accumulated Deficit [Member]
Balance at Dec. 31, 2015 $ 12,206       $ 13   $ 368,214   $ 996 $ (357,017)
Balance (in shares) at Dec. 31, 2015         13,003,893          
Share-based compensation 1,080           1,080      
Issuance of common stock under employee stock purchase plan 6           6      
Issuance of common stock under employee stock purchase plan (in shares)         30,744          
Sale/Issuance of common stock 19,478       $ 9   19,469      
Sale/Issuance of common stock (in shares)         8,673,253          
Foreign currency translation adjustment and accumulated other comprehensive income 262               262  
Net loss (22,046)                 (22,046)
Balance at Dec. 31, 2016 $ 10,986       $ 22   388,769   1,258 (379,063)
Balance (in shares) at Dec. 31, 2016 21,707,890       21,707,890          
Share-based compensation $ 753           753      
Issuance of common stock under employee stock purchase plan 1           1      
Issuance of common stock under employee stock purchase plan (in shares)         1,200          
Sale/Issuance of common stock 12,716 $ 8,767     $ 12   12,704 $ 8,767    
Sale/Issuance of common stock (in shares)       10,000 12,237,079          
Conversion of Series B Convertible Preferred Stock into common stock   23       $ 23        
Conversion of Series B Convertible Preferred Stock into common stock (share)       (7,569)   22,706,319        
Issuance of common stock as part of Azaya Therapeutics acquisition, net 2,311       $ 1   2,310      
Issuance of common stock as part of Azaya Therapeutics acquisition, net (shares)         1,173,241          
Beneficial conversion feature related to Series B Convertible Preferred Stock   3,977           3,977    
Accretion of beneficial conversion feature related to Series B Convertible Preferred Stock   $ (3,977)           $ (3,977)    
Foreign currency translation adjustment and accumulated other comprehensive income 129               129  
Net loss (22,686)                 (22,686)
Balance at Dec. 31, 2017 $ 13,000       $ 58   $ 413,304   $ 1,387 $ (401,749)
Balance (in shares) at Dec. 31, 2017 57,825,729   2,431   57,825,729